Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD134 Purified

Anti-Hu CD134 Purified

Regulatory status

RUO

Antigen

CD134

Clone

Ber-ACT35

Format

Purified

Reactivity

Non-human primates, Human

Application

ELISA, IP, WB, FC (QC tested), IHC(F), IHC(P)

Variant

0.1 mg

11-152-C100

In stock

130.00 USD

0.025 mg

11-152-C025

Delivery 1 week

65.00 USD

Variant

0.1 mg

11-261-C100

In stock

130.00 USD

0.1 mg

11-261-C100

In stock

65.00 USD

Contact distributor

Product details

Description

Images

References

Isotype

Mouse IgG1 kappa

Specificity

The mouse monoclonal antibody Ber-ACT35 (also known as ACT35) recognizes an extracellular epitope of CD134 (TNFRSF4, OX40), an approximately 50 kDa type I transmembrane glycoprotein expressed on activated T cells.

Workshop

HLDA VI: WS Code C-31

Application

ELISA, IP, WB, FC (QC tested), IHC(F), IHC(P)

Application details

Flow cytometry: Recommended dilution: 3-6 μg/ml.
Immunohistochemistry: Recommended dilution: 5-10 μg/ml.

Reactivity

Non-human primates, Human

Immunogen

HTLV 1-transformed HUT-102 cells

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

TNFRSF4, OX40, ACT35, IMD16, TXGP1L

Antigen description

CD134 (TNFRSF4, also known as OX40) is a type I transmembrane glycoprotein of TNF/NGF receptor family expressed on activated T cells, fibroblasts, and hematopoietic precursors. Binding to its ligand (OX40L, TNFSF4) on antigen presenting cells gives to the T cell costimulatory signal, and this interaction results also in B cell proliferation and influences T cell memory pool. CD134 is upregulated at sites of inflammation, especially in case of multiple sclerosis and psoriatic lesions.

Entrez Gene ID 7293

UniProt ID P43489

Flow cytometry analysis (surface staining) of human PHA-activated leukocytes with anti-human CD134 (Ber-ACT35) purified, GAM APC.

Product specific references:

Endl J, Rosinger S, Schwarz B, Friedrich SO, Rothe G, Karges W, Schlosser M, Eiermann T, Schendel DJ, Boehm BO: Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes. 2006 Jan;55(1):50-60.
PubMed

Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ: Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol. 2000 Aug;11(8):1426-38.
PubMed

Jones D, Fletcher CD, Pulford K, Shahsafaei A, Dorfman DM: The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood. 1999 May 15;93(10):3487-93.
PubMed

Li M, Zhang Y: The effect of anti-human CD134 monoclonal antibody on phytohemagglutinin-induced mRNA expression of perforin in peripheral blood mononuclear cells. Cell Mol Immunol. 2005 Dec;2(6):467-71.
PubMed

Tanijiri T, Shimizu T, Uehira K, Yokoi T, Amuro H, Sugimoto H, Torii Y, Tajima K, Ito T, Amakawa R, Fukuhara S: Hodgkin's reed-sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol. 2007 Sep;82(3):576-84.
PubMed

Willett BJ, McMonagle EL, Ridha S, Hosie MJ: Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J Virol. 2006 Apr;80(7):3386-94.
PubMed

Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, Kwak LW, Liu YJ: Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol. 2013 Oct 1;191(7):3641-50.
PubMed

Variant

0.1 mg

11-152-C100

In stock

130.00 USD

0.025 mg

11-152-C025

Delivery 1 week

65.00 USD

Variant

0.1 mg

11-261-C100